RNS Number : 9155X GSK PLC 20 February 2025   GSK plc (the 'Company') Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of Ordinary Shares and American Depositary Shares This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary Shares and American Depositary Shares ('ADSs') made in 2022 under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale of Ordinary Shares and ADSs to meet tax liabilities.  In accordance with the shareholder approved 2017 Remuneration Policy and the DABP rules, the awards comprised a mandatory bonus deferral only. The three-year restricted period for the awards commenced on 15 February 2022 and ended on 17 February 2025 for Ordinary Shares and 18 February 2025 for ADSs. Dividends accrued on the awards during the restricted period. The awards were granted in 2022 as restricted awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants. The closing price of Ordinary Shares of GSK plc on 17 February 2025 was £14.195 and the closing price of ADSs of GSK plc on 18 February 2025 was $36.61.     Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief Executive Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option c) Price(s) and volume(s) Price(s) Volume(s) £0.00 81,703   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   N/A   1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief Executive Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.1818 38,459   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Dr Hal Barron b) Position/status Non-Executive Director c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument American Depositary Shares ('ADSs')   ISIN: US37733W2044 b) Nature of the transaction The vesting of an award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan c) Price(s) and volume(s) Price(s) Volume(s) $0.00 45,690 d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-18 f) Place of the transaction   N/A   1. Details of PDMR/person closely associated with them ('PCA') a) Name Dr Hal Barron b) Position/status Non-Executive Director c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument American Depositary Shares ('ADSs')   ISIN: US37733W2044 b) Nature of the transaction The sale of ADSs' to meet tax liabilities on the vesting of an award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan. c) Price(s) and volume(s) Price(s) Volume(s) $36.6355   24,623 d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-18 f) Place of the transaction   New York Stock Exchange (XNYS) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Diana Conrad b) Position/status Chief People Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option c) Price(s) and volume(s) Price(s) Volume(s) £0.00 12,825   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   N/A   1. Details of PDMR/person closely associated with them ('PCA') a) Name Diana Conrad b) Position/status Chief People Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2070   6,883   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   London Stock Exchange (XLON)   1. Details of PDMR/person closely associated with them ('PCA') a) Name James Ford b) Position/status SVP and Group General Counsel, Legal and Compliance c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option c) Price(s) and volume(s) Price(s) Volume(s) £0.00 15,792   d) Aggregated information   N/A (single transaction)   Aggregated volume Price                           e) Date of the transaction 2025-02-17 f) Place of the transaction   N/A   1. Details of PDMR/person closely associated with them ('PCA') a) Name James Ford b) Position/status SVP and Group General Counsel, Legal and Compliance c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2001   7,441   d) Aggregated information   N/A (single transaction)   Aggregated volume Price                           e) Date of the transaction 2025-02-17 f) Place of the transaction   London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Sally Jackson b) Position/status SVP, Global Communications and CEO Office c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option c) Price(s) and volume(s) Price(s) Volume(s) £0.00 7,371   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   N/A   1. Details of PDMR/person closely associated with them ('PCA') a) Name Sally Jackson b) Position/status SVP, Global Communications and CEO Office c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.2000 3,477   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   London Stock Exchange (XLON)   1. Details of PDMR/person closely associated with them ('PCA') a) Name Luke Miels b) Position/status Chief Commercial Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option c) Price(s) and volume(s) Price(s) Volume(s) £0.00 26,851   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   N/A   1. Details of PDMR/person closely associated with them ('PCA') a) Name Luke Miels b) Position/status Chief Commercial Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.1950   618   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   London Stock Exchange (XLON)   1. Details of PDMR/person closely associated with them ('PCA') a) Name Shobie Ramakrishnan b) Position/status Chief Digital and Technology Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument American Depositary Shares ('ADSs')   ISIN: US37733W2044 b) Nature of the transaction The vesting of an award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan c) Price(s) and volume(s) Price(s) Volume(s) $0.00 2,786 d) Aggregated information   N/A (single transaction)   Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction   N/A     1. Details of PDMR/person closely associated with them ('PCA') a) Name Shobie Ramakrishnan b) Position/status Chief Digital and Technology Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument American Depositary Shares ('ADSs')   ISIN: US37733W2044 b) Nature of the transaction The sale of ADSs' to meet tax liabilities on the vesting of an award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan. c) Price(s) and volume(s) Price(s) Volume(s) $36.6355   1,502 d) Aggregated information   N/A (single transaction)   Aggregated volume Price e) Date of the transaction 2025-02-18 f) Place of the transaction   New York Stock Exchange (XNYS)     1. Details of PDMR/person closely associated with them ('PCA') a) Name David Redfern b) Position/status President Corporate Development c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option c) Price(s) and volume(s) Price(s) Volume(s) £0.00 17,805   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   N/A   1. Details of PDMR/person closely associated with them ('PCA') a) Name David Redfern b) Position/status President Corporate Development c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.1906   8,390   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   London Stock Exchange (XLON)   1. Details of PDMR/person closely associated with them ('PCA') a) Name Regis Simard b) Position/status President, Global Supply Chain c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option c) Price(s) and volume(s) Price(s) Volume(s) £0.00 16,172   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   N/A     1. Details of PDMR/person closely associated with them ('PCA') a) Name Regis Simard b) Position/status President, Global Supply Chain c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.1954   7,620   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2054-02-17 f) Place of the transaction   London Stock Exchange (XLON)   1. Details of PDMR/person closely associated with them ('PCA') a) Name Phil Thomson b) Position/status President, Global Affairs c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option c) Price(s) and volume(s) Price(s) Volume(s) £0.00 11,220   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   N/A   1. Details of PDMR/person closely associated with them ('PCA') a) Name Phil Thomson b) Position/status President, Global Affairs c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.1929   5,287   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   London Stock Exchange (XLON)   1. Details of PDMR/person closely associated with them ('PCA') a) Name Deborah Waterhouse b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option c) Price(s) and volume(s) Price(s) Volume(s) £0.00 11,841   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   N/A 1. Details of PDMR/person closely associated with them ('PCA') a) Name Deborah Waterhouse b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GSK plc b) LEI 5493000HZTVUYLO1D793 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63 b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2022 under the Company's 2017 Deferred Annual Bonus Plan c) Price(s) and volume(s) Price(s) Volume(s) £14.1985   5,580   d) Aggregated information   N/A (single transaction)   Aggregated volume Price     e) Date of the transaction 2025-02-17 f) Place of the transaction   London Stock Exchange (XLON)         This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  DSHSEAFLSEISEEE